Testing the Addition of a Type of Drug Called Immunotherapy to the Usual Chemotherapy Treatment for Non-small Cell Lung Cancer, an ALCHEMIST Treatment Trial (Chemo-IO [ACCIO])
National Cancer Institute (NCI)
National Cancer Institute (NCI)
AstraZeneca
Eli Lilly and Company
National Institutes of Health Clinical Center (CC)
National Cancer Institute (NCI)
Weill Medical College of Cornell University
Seagen Inc.
Seagen Inc.
Hoffmann-La Roche
Eli Lilly and Company
Pfizer
Eli Lilly and Company
Merck Sharp & Dohme LLC
Merck Sharp & Dohme LLC
Merck Sharp & Dohme LLC
Bristol-Myers Squibb
ImmunityBio, Inc.
BeOne Medicines
Bristol-Myers Squibb
National Cancer Institute (NCI)
AstraZeneca
Hoffmann-La Roche
ImmunityBio, Inc.
Genmab
Hoffmann-La Roche
Mirati Therapeutics Inc.
Taiho Oncology, Inc.
M.D. Anderson Cancer Center
AstraZeneca
Gustave Roussy, Cancer Campus, Grand Paris
H. Lee Moffitt Cancer Center and Research Institute
Incyte Corporation
Bristol-Myers Squibb
Takeda
AstraZeneca
AstraZeneca
Revolution Medicines, Inc.
PrECOG, LLC.
University of Vermont
Daiichi Sankyo
TheRas, Inc., d/b/a BBOT (BridgeBio Oncology Therapeutics)
BeOne Medicines
Immutep S.A.S.
Gilead Sciences
Pfizer
Hoffmann-La Roche
AstraZeneca
Hoffmann-La Roche
Revolution Medicines, Inc.
Qilu Pharmaceutical Co., Ltd.